Assignee
ANYGEN CO LTD
KR·5 granted patents·8 pending applications·4 citations·filing 2005–2022
Top patents by PatentIndex Score
13 records- 0180US7572923B2Indirubin derivatives having anticancer property against human cancer cell lineANYGEN CO LTD·Filed 2005·Granted Aug 11, 2009·4 cites·9 claims
- 0256US2025109170A1Method for manufacturing ganirelixANYGEN CO LTD·Filed 2022·Application pending·0 cites
- 0354US2017252453A9Transmucosal delivery of pharmaceutical active substancesANYGEN CO LTD·Filed 2014·Application pending·0 cites
- 0453US2025340591A1Composition for preventing or treating inflammatory bowel disease containing novel compoundANYGEN CO LTD·Filed 2022·Application pending·0 cites
- 0552US2025032629A1Novel nucleolin-binding peptide and use thereofANYGEN CO LTD·Filed 2021·Application pending·0 cites
- 0649US2023287044A1Novel antibacterial peptide and use thereofANYGEN CO LTD·Filed 2021·Application pending·0 cites
- 0749US2009041673A1Thermally Crosslinked Contrast AgentsANYGEN CO LTD·Filed 2007·Application pending·0 cites
- 0848US2024299487A1Antiviral composition comprising a nucleolin-binding peptideANYGEN CO LTD·Filed 2022·Application pending·0 cites
- 0947US7812177B2Potassium channel opener having benzofuroindole skeletonANYGEN CO LTD·Filed 2006·Granted Oct 12, 2010·0 cites·5 claims
- 1045US2023212222A1Composition for anti-diabetes and anti-obesity comprising novel compoundANYGEN CO LTD·Filed 2021·Application pending·0 cites
- 1144US12383605B2Exenatide analog and use thereofANYGEN CO LTD·Filed 2020·Granted Aug 12, 2025·0 cites·3 claims
- 1238US11103557B2Exenatide analogue and use thereofANYGEN CO LTD·Filed 2015·Granted Aug 31, 2021·0 cites·4 claims
- 1338US10285979B2Breast cancer therapeutic agent containing 5′-hydroxy-5-nitro-indirubin-3′-oxime as active ingredientANYGEN CO LTD·Filed 2017·Granted May 14, 2019·0 cites·4 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →